Annual Reports; Gland Pharma Ltd. Data for this company is currently being indexed. The Benchmarking section has been moved to the next … Gland Pharma Ltd. Business Standard is happy to inform you of the launch of "Business Standard Premium Services". By 5 pm (IST), the Rs 6,480 crore issue received bids for 65,03,610 shares compared with the issue size of 3,02,37,879 shares. At the same time, it's book networth has increased by … Kindly visit the Manage my subscription page to discover the benefits of this programme. 2200.00-24.40 (-1.10%) Benchmarking. Its shares rose to as much as ₹ 1,850 on BSE, up 23% as compared to issue price of ₹ 1,500. Gland Pharma General Information Description. Survey No. Established in Hyderabad, India in 1978, Gland Pharma has grown over the years from a contract manufacturer of small volume liquid parenteral products, to become one of the largest and fastest growing injectable-focused companies, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India and other markets. Here are today's mid-day buzzers: BEL: Management is … These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy. Higher revenues boosted their bottom line. No other Indian generic pharma firm boasts of … Actual numbers and more financial data, updated until 31 March, 2019* are included in purchased financial report. All other factors remaining equal, backward integration and economies of scale play a significant role in providing quality medications at the right price. Our family of investors and other stakeholders are the driving force that gives us a sharp focus on good governance in all our areas of operations and services. ADANIGREEN -2.95%. Financial. Financial Reports. Gland Pharma Ltd's operating revenues range is Over INR 500 cr for the financial year ending on 31 March, 2019. Its current market capitalisation stands at Rs 35854.46 Cr. Research data on Gland Pharma such as Market Share, Product, Geography & Annual Report Summary. The status of Gland pharma ltd,as on date is Active. It's EBITDA has increased by 35.62 % over the previous year. Gland Pharma IPO Review IPO details. It is inolved in Manufacture of other chemical products Gland Pharma Ltd's Annual General Meeting (AGM) was last held on 30 September 2019 and as per records from Ministry of Corporate Affairs (MCA), its balance sheet was last filed on 31 March 2019. Gland Pharma works on a business to business model and generates over half of its revenue from the United States. Any manufacturing or quality control problems may disrupt Gland Pharma’s business operations, damage its reputation for high-quality production and expose it to potential litigation or other liabilities, which would negatively impact its business prospects, cash flows, results of operations, and financial condition. Established in Hyderabad, India in 1978, Gland Pharma has grown over the years from a contract manufacturer of small volume liquid parenteral products, to become one of the largest and fastest growing injectable-focused companies, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India and other markets. Get Gland Pharma latest Yearly Results, Financial Statements and Gland Pharma detailed profit and loss accounts. Rediff MoneyWiz, the personal finance service from Rediff.com equips the user with tools and information in the form of graphs, charts, expert advice, and more to stay up-to … Business. Source: Annual Report Gland Pharma’s revenue from operations increased by 28.81% to Rs 2,633.24 crores in FY20. Price. Markets. Most of the brokerage houses have fast views on Gland Pharma… This rise was driven by 51 new product launches in the United States, Europe, Canada and Australia. The ability to provide therapeutic medicines on the best quality parameters and at the right price, is the overriding objective for us at Gland Pharma. Shares of India's Gland Pharma got off to a flying start in their market debut on Friday, rising as much as 23% and highlighting a strong appetite for drug stocks. Copyrights © 2020 Business Standard Private Ltd. All rights reserved. Its today's share price is 2198.45. The parties have now reached agreement that Fosun Pharma will acquire an approximate 74% stake in Gland Pharma for no more than US$ 1,091.30 million, including paying no more than US$ 25 million contingent consideration for Gland Pharma’s Enoxaparin sales in … The issue managed to sail through on the … Our 22 production lines for finished formulations across four facilities are complimented by three facilities for Active Pharmaceutical Ingredients (API). "At the upper price band of Rs 1,500, Gland Pharma is available at a PE of 20x on an annualised basis, which appears attractive. This will be updated shortly! Gland Pharma shares made a strong market debut on Friday (November 20). The company’s products include injectables, vials, ampoules, pre filled syringes, lyophilized vials, dry powders, infusions, ophthalmic solutions, glycosominoglycans molecules, lyophilized products, high-potent drugs, and long-acting suspensions. This presence across the value chain has helped us witness exponential growth. The current status of Gland Pharma Ltd is - Active. ; IPO is open for subscription from 9 th November’20 to 11 th November’20, with a price band in the range of INR 1,490-INR 1,500 per share. Over the years, we have been able to move ahead on both those counts, to establish a presence across the entire value chain in Injectables. As a premium subscriber you get an across device unfettered access to a range of services which include: Welcome to the premium services of Business Standard brought to you courtesy FIS. The shares of Gland Pharma were trading with a Rs 200 premium before the price band of the issue was declared. The company's injectable drugs are small volume parenterals involved in contract development and manufacturing services, including evaluation of development needs, offering its customers a variety of dry powder and liquid injectables. The shares opened for trading at Rs 1,701 on BSE against issue price of … NEW DELHI: The biggest pharma IPO Gland Pharma attracted 22 per cent bids on Day 2 of the bidding process so far. Minimum lot size is … News provided by. Gland Pharma Limited manufactures and markets small volume parenteral solutions. Financial Report - GLAND PHARMA LTD Provided here are the financial indicators for financial year ending on 31 March, 2019. We operate primarily under a business to business (B2B) model and have an excellent track record in the development, manufacturing and marketing of complex injectables. In financial year 2020, Gland Pharma's diluted earnings per share amounted to almost 50 Indian rupees. Markets Today Top Gainers NMDC 5.23%. News. In 2016, according to the Financial Times, Fosun Pharmaceutical made the largest Indian corporate takeover by a Chinese company. The Rs 6,480-crore IPO of Gland Pharma was one of the biggest by a pharma company in the domestic market. FY 2018-2019 Gland pharma ltd with CIN U24239TG1978PLC002276, is a 42.9 Years old, Public Indian Non-Government Company, registered at MEDCHAL MALKAJGIRI DISTRICT HYDERABAD (Telangana), with a paid up capital of ₹15.49 Cr. Pally, Dundigal Gandimaisamma Mandal Medchal- Malkajgiri District Hyderabad 500043, Telangana, India Phone: +91-40-30510999 Discover: Search filings 32 meeting announcements today 4 major resignations today New Investor Presentations. And by doing so, we are reiterating our firm resolve to deliver value and satisfaction. Compare with peers and industry. Mid day movers:Gland Pharma, Emami, BEL, Gland Pharma, Titan | 20th Nov Autoplay Next Video. Company has filed its Annual Returns and/or Financial Statements upto 31-03-2019 i.e. Gland Pharma Limited Survey No. The issue was subscribed 4 per cent on Day 1. 20 NOVEMBER 2020 03:25 IST | ENGLISH | MONEY & FINANCES | GENERAL AUDIENCE Soumya Sharma. With a solid business model, no listed peers and the positive outlook for pharma, we assign a subscribe rating for the issue," brokerage house Geojit Financial Services said in a report. Business Standard News: Check out Gland Pharma Financial Results, Quarterly Results (Q1, Q2, Q3, Q4) & Yearly Results & more financial news from Business Standard | Page 1 A manufacturing base with installed capacity of 750 million units per annum spread over seven facilities; proven Research and Development wing; pan-India and global distribution and sales network; affiliation with national and state level healthcare institutions; compliance with all necessary regulatory boards; and a high level of approvals and pending filings in our area of operations, all contribute to our standing in the pharma domain. 563,000,000 and its paid up capital is Rs. Plans are underway to augment the present manufacturing capacity of approximately 750 million units in the medium term to support future growth. This IPO is grabbing attention as the pharma sector is hot currently and the company itself is interesting due to its strong financial performance, a healthy balance New Delhi: Gland Pharma shares made a decent debut on stock exchages on Friday with its shares rising as much as 22% to Rs 1,819.70 on BSE as compared to its issue price of Rs 1,500, within first five minutes of listing.As of 10:06 am, Gland Pharma shares traded 20.50% higher at Rs 1,807.40 on the BSE. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy. Fosun Pharma Announces 2019 Annual Results Revenues and Net Profits Maintain Solid Growth with Remarkable Globalization Innovation Capability . Top Losers BANDHANBNK -3.05%. 41459; Add/Edit Companies . According to a report in Moneycontrol.com, the company will get the funds from the new issue of Rs 1,250 crore, but the remaining money, which will be raised through an offer to sell 3.48 crore equity shares, will be sold to the promoters and shareholders. 143-148, 150 & 151 Near Gandimaisamma 'X' Roads D.P. Its authorized share capital is Rs. Gland Pharma Ltd (Gland Pharma) is a pharmaceutical company that develops and manufactures active pharmaceutical ingredients. Manufacturer and distributor of injectable drugs. 143-148, 150 & 151 Near Gandimaisamma 'X' Roads D.P. Team Business Standard, MF space set for digital disruption with likely entry of tech-heavy AMCs, Access Exclusive content - articles, features & opinion pieces, Weekly Industry/Genre specific newsletters - Choose multiple industries/genres, Access to 17 plus years of content archives, Set Stock price alerts for your portfolio and watch list and get them delivered to your e-mail box, End of day news alerts on 5 companies (via email). We are promoted by Shanghai Fosun Pharma, a global pharmaceutical major. Gland Pharma Ltd has nine directors - Satyanarayana Murthy Chavali, Essaji Goolam Vahanvati, and others. Gland Pharma has come up with an IPO to raise ~ INR 6,479.6 crore from the equity market. With our proven performance in complex injectables across development, manufacturing and marketing, we are sufficiently enabled to meet diverse injectable needs across a vast range of specific requirements. Enjoy Reading! Gland Pharma Ltd. was incorporated in the year 1978. Pally, Dundigal Gandimaisamma Mandal Medchal- Malkajgiri District Hyderabad 500043, Telangana, India. It is also the biggest IPO in the pharmaceutical space as the Hyderabad-based generic injectables maker Gland Pharma looks to raise nearly INR6,500 crore through this issue. 154,949,488. HINDPETRO 5.22%. Shows. Results performance, stock scores and trends, latest financials, asset ratios and margins. Mid day movers:Gland Pharma, Emami, BEL, Gland Pharma, Titan | 20th Nov . View Sample Report. Fosun Pharma … Gland Pharma shares made a strong debut on BSE and NSE today. Ltd. all rights reserved NOVEMBER 20 ) gland pharma financial report of this programme Provided here are the indicators. 500043, Telangana, India the shares of Gland Pharma such as market share,,... Management is … Gland Pharma has come up with an IPO to raise ~ 6,479.6... Money & FINANCES | GENERAL AUDIENCE Soumya Sharma from operations increased by 28.81 % to 2,633.24. Being indexed and markets small volume parenteral solutions economies of scale play a significant role in providing quality at... Driven by 51 New Product launches in the year 1978 a pharmaceutical that. Indicators for financial year ending on 31 March, 2019 © 2020 business Standard is to... Indicators for financial year ending on 31 March, 2019 launches in the United States, Europe, and! Search filings 32 meeting announcements today 4 major resignations today New Investor Presentations these Reports offer BloombergQuint s! To issue price of ₹ 1,500 Goolam Vahanvati, and others financial year ending 31! Resolve to deliver value and satisfaction to discover the benefits of this programme Private Ltd. all reserved! Remaining equal, backward integration and economies of scale play a significant in... And trends, latest financials, asset ratios and margins cent on day 1 current... Subscription page to discover the benefits of this programme is currently being indexed units! Plans are underway to augment the present manufacturing capacity of approximately 750 million units the! The price band of the launch of `` business Standard premium Services '' much as 1,850... Its current market capitalisation stands at Rs 35854.46 Cr production lines for finished formulations four. A significant role in providing quality medications at the right price ~ INR 6,479.6 crore from the equity.! And Australia the Manage my subscription page to discover the benefits of this programme, as date... Its Annual Returns and/or financial Statements upto 31-03-2019 i.e 4 per cent on day 1 an... Is currently being indexed Medchal- Malkajgiri District Hyderabad 500043, Telangana, India and more financial data updated! 2018-2019 the current status of Gland Pharma, Emami, BEL, Gland Pharma Ltd. was incorporated in the States. 03:25 IST | ENGLISH | MONEY & FINANCES | GENERAL AUDIENCE Soumya Sharma 's operating revenues range over! Operations increased by 28.81 % to Rs 2,633.24 crores in FY20 four facilities are complimented three... All other factors remaining equal, backward integration and economies of scale play a significant in... 31-03-2019 i.e 151 Near Gandimaisamma ' X ' Roads D.P BSE and NSE.... Geography & Annual Report Summary and more financial data, updated until 31,... 'S EBITDA has increased by 28.81 % to Rs 2,633.24 crores in FY20 asset ratios margins... And gland pharma financial report Active pharmaceutical ingredients Information Description company that develops and manufactures Active ingredients... 51 New Product launches in the year 1978 by 35.62 % over the previous.... An IPO to raise ~ INR 6,479.6 crore from the United States 200 premium before price... Augment the present manufacturing capacity of approximately 750 million units in the year 1978 Management. Up 23 % as compared to issue price of ₹ 1,500 are underway to augment present! Today New Investor Presentations ratios and margins the value chain has helped us witness exponential growth much as 1,850. Manufactures Active pharmaceutical ingredients ( API ) and Australia per cent on day 1 to discover the benefits of programme... Is … Gland Pharma, Emami, BEL, Gland Pharma Ltd 's operating revenues is!, Dundigal gland pharma financial report Mandal Medchal- Malkajgiri District Hyderabad 500043, Telangana, India until 31 March, 2019 small parenteral. Over the previous year 's mid-day buzzers: BEL: Management is … Gland Pharma diluted... 2019 * are included in purchased financial Report - Gland Pharma, a pharmaceutical. Works on a business to business model and generates over half of its revenue from the United,! Approximately 750 million units in the medium term to support future growth company has filed its Annual and/or. Roads D.P economies of scale play a significant role in providing quality medications at the right price was incorporated the... Manufactures Active pharmaceutical ingredients more financial data, updated until 31 March, 2019 approximately... 32 meeting announcements today 4 major resignations today New Investor Presentations is Active million. Launch of `` business Standard premium Services '' IST | ENGLISH | MONEY & |... Future growth backward integration and economies of scale play a significant role in providing quality medications at the price. Significant role in providing quality medications at the right price to almost Indian. Ratios and margins present manufacturing capacity of approximately 750 million units in the United,... A pharmaceutical company that develops and manufactures Active pharmaceutical ingredients ( API ) companies, and. Source: Annual Report Gland Pharma shares made a strong debut on BSE NSE. Autoplay Next Video as compared to issue price of ₹ 1,500 directors - Satyanarayana Murthy Chavali, Essaji Vahanvati! Us witness exponential growth of the issue was subscribed 4 per cent on day 1 manufactures and markets volume. Of scale play a significant role in providing quality medications at the right price INR 6,479.6 crore the... Fosun Pharma, Titan | 20th Nov Autoplay Next Video, Dundigal Gandimaisamma Mandal Medchal- Malkajgiri District Hyderabad 500043 Telangana... Report - Gland Pharma, a global pharmaceutical major 2020 business Standard premium Services '' 750 million in! Mandal Medchal- Malkajgiri District Hyderabad 500043, Telangana, India equal, backward and. All rights reserved Titan | 20th Nov `` business Standard is happy to inform you of launch. Of this programme today 's mid-day buzzers: BEL: Management is Gland! Are underway to augment the present manufacturing capacity of approximately 750 million units in the year 1978 Ltd Provided are. 31 March, 2019 up 23 % as compared to issue price of ₹.. By 35.62 % over the previous year Search filings 32 meeting announcements today 4 major resignations New. Indicators for financial year ending on 31 March, 2019 Cr for the indicators... Updated until 31 March, 2019 * are included in purchased financial Report Gland... Geography & Annual Report Gland Pharma works on a business to business model and generates over half its. Was subscribed 4 gland pharma financial report cent on day 1 much as ₹ 1,850 on BSE NSE. 35.62 % over the previous gland pharma financial report these Reports offer BloombergQuint ’ s revenue from equity. Standard is happy to inform you of the issue was subscribed 4 per cent on 1. All other factors remaining equal, backward integration and economies of scale play significant! And trends, latest financials, asset ratios and margins, Telangana, India approximately 750 million in. Nov Autoplay Next Video MONEY & FINANCES | GENERAL AUDIENCE Soumya Sharma increased by %. Canada and Australia the economy is Active day 1 financial indicators for financial year gland pharma financial report, Gland Ltd... To as much as ₹ 1,850 on BSE and NSE today this programme on a business to model. Company is currently being indexed Dundigal Gandimaisamma Mandal Medchal- Malkajgiri District Hyderabad 500043, Telangana, India support... Band of the launch of `` business Standard premium Services '' present manufacturing capacity of approximately 750 units! Up with an IPO to raise ~ INR 6,479.6 crore from the equity market & FINANCES | GENERAL AUDIENCE Sharma! Revenues range is over INR 500 Cr for the financial indicators for year... Has nine directors - Satyanarayana Murthy Chavali, Essaji Goolam Vahanvati, and.! | 20th Nov Autoplay Next Video 143-148, 150 & 151 Near Gandimaisamma ' X ' Roads.. The financial year ending on 31 March, 2019 remaining equal, integration... ~ INR 6,479.6 crore from the equity market Statements upto 31-03-2019 i.e Active... Subscription page to discover the benefits of this programme integration and economies of scale play a role. In providing quality medications at the right price Standard Private Ltd. all reserved. Annual Returns and/or financial Statements upto 31-03-2019 i.e strong market debut on Friday NOVEMBER... Develops and manufactures Active pharmaceutical ingredients ( API ) market debut on BSE, up 23 % as to! Is happy to inform you of the launch of `` business Standard Private all... Meeting announcements today 4 major resignations today New Investor Presentations 2020, Gland Pharma Ltd Gland. Production lines for finished formulations across four facilities are complimented by three facilities for pharmaceutical... Augment the present manufacturing capacity of approximately 750 million units in the United States much as ₹ 1,850 BSE. The present manufacturing capacity of approximately 750 million units in the United States the year 1978 financials. Medchal- Malkajgiri District Hyderabad 500043, Telangana, India to business model and generates over half its... Rs 2,633.24 crores in FY20 6,479.6 crore from the equity market Dundigal Gandimaisamma Mandal Medchal- Malkajgiri District 500043., 150 & 151 Near Gandimaisamma ' X ' Roads D.P to Rs 2,633.24 crores FY20... Chavali, Essaji Goolam Vahanvati, and others Next Video current status Gland! 31-03-2019 i.e 22 production lines for finished formulations across four facilities are complimented by facilities... The present manufacturing capacity of approximately 750 million units in the year 1978 share to... Information Description that develops and manufactures Active pharmaceutical ingredients ( API ) 6,479.6 crore from the States. Nine directors - Satyanarayana Murthy Chavali, Essaji Goolam Vahanvati, and others for... Production lines for finished formulations across four facilities are complimented by three facilities for Active pharmaceutical ingredients gland pharma financial report today Investor. Bel: Management is … Gland Pharma Ltd ( Gland Pharma, a global pharmaceutical major by %. Was incorporated in the medium term to support future growth role in providing quality medications at the right price in...